Culverwell Anthony James 4

What Happened

• Anthony James Culverwell, a director of Quoin Pharmaceuticals, was granted a derivative award of 21,709 ADSs on February 4, 2026. The filing lists an acquisition at $0.00 (transaction code A), meaning this was an awarded/compensatory grant rather than an open-market purchase. Each ADS represents 35 ordinary shares, so the award equals 21,709 × 35 = 759,815 ordinary shares on an underlying-share basis. The award vests over four years per the schedule below.

Key Details

• Transaction date: 2026-02-04; Filing date: 2026-02-06 (timely).
• Amount: 21,709 ADSs (derivative award) at $0.00; equivalent to 759,815 ordinary shares (1 ADS = 35 ordinary shares) per footnote.
• Vesting (Footnote F2): 20% vests Feb 4, 2027; 20% Feb 4, 2028; 20% Feb 4, 2029; 40% Feb 4, 2030.
• Shares owned after transaction: not specified in the provided filing.
• Nature: derivative award (compensatory grant) — not an immediate sale or market purchase.

Context

• This was a compensatory grant to a director that vests over time; it does not represent an immediate cash transaction or sale of shares. Awards to directors are common as long-term incentive/retention tools and should not be read as an immediate bullish or bearish trade signal. The ADS conversion means the headline ADS count represents a much larger number of underlying ordinary shares (multiply ADSs × 35).